Pre-Clinical Development

CROs Face Stagnant Preclinical Market Growth

CROs Face Stagnant Preclinical Market Growth

By Zachary Brennan

An uptick in the outsourcing of preclinical trials is expected as pharmaceutical companies look to restructure and cut costs, but that increase won't necessarily begin in 2013, according to an analyst.

RXi targets dermal cells with RNA delivery method

RXi targets dermal cells with RNA delivery method

By Nick Taylor

RXi Pharmaceuticals has applied its sd-rxRNA to dermal cells, establishing the efficacy of the technology as it seeks to move it on to the next stage of development, a company VP told in-PharmaTechnologist.